Immune checkpoint inhibitors are revolutionizing the treatment of cancer, but new research challenges the central dogma of how these drugs work. This research, published in the prestigious Journal of Clinical Investigation, shows for the first time that often-overlooked immune cells called Natural Killer (NK) cells play a crucial role in responding to checkpoint inhibitors.
Natural Killer cells, shown in green, are attacking a mouse tumor. These often-overlooked cells may be key to cancer immunotherapy. Blood vessels are shown in blue. Credit: Dr. Michele Ardolino and Dr. Brian Weist.
"Checkpoint inhibitors work by waking up the body's own immune system and unleashing an immune attack on cancer cells," explained co-senior author Dr. Michele Ardolino, a scientist at The Ottawa Hospital and assistant professor at the University of Ottawa. "For many years, everyone assumed that checkpoint inhibitors targeted immune cells called T cells. But our research shows that they also target Natural Killer cells and these cells play a key role in the how this treatment works."
Dr. Ardolino led the study together with Dr. David Raulet, professor at the University of California at Berkeley.
"In the cancer immunotherapy field there has been a singular focus on mobilizing anti-tumor T cells, said Dr. Raulet. "We believe that NK cells have an important place at the table. Checkpoint therapy combined with other NK-directed immunotherapies may enable us to target many types of tumors that are currently non-responsive to available therapies."
T cells and NK cells can both recognize and kill cancer cells, but they do so in very different ways. NK cells recognize patterns of changes on cancer cells and are the immune system's first line of defense. A T cell, on the other hand, recognizes a single abnormal molecule on a cancer cell and initiates a more focused attack.
In the current study, Dr. Ardolino and Dr. Raulet and their colleagues investigated the effect of checkpoint inhibitors in various mouse models of cancer. They found that checkpoint inhibitors could shrink tumours even in mice with no anti-cancer T cells, meaning that some other kind of cell must be responding to the checkpoint inhibitors. When the mice were depleted of NK cells, it greatly reduced or eliminated the anti-cancer effect of the checkpoint inhibitors. They also showed that NK cells produce the same checkpoint receptor molecules that T cells do, meaning they can respond directly to checkpoint inhibitors.
"This research helps solve a mystery that's been seen in the clinic, where certain cancers are very susceptible to checkpoint inhibitors even though their T cells don't seem to be activated," said co-lead author Jonathan Hodgins, a PhD student at The Ottawa Hospital and the University of Ottawa. "If we're right, NK cells are probably being activated in these patients."
The researchers are now investigating approaches to further enhance the cancer-killing ability of NK cells.
"My dream is that when people come to the hospital with cancer, we'll be able to take a biopsy and determine not only the mutations in their cancer, but also profile how their immune system is interacting with their cancer," said Dr. Ardolino. "Then we would give the patient the immunotherapy treatments that is most likely to work for them."
This article has been republished from materials provided by The Ottawa Hospital. Note: material may have been edited for length and content. For further information, please contact the cited source.
Joy Hsu, Jonathan J. Hodgins, Malvika Marathe, Chris J. Nicolai, Marie-Claude Bourgeois-Daigneault, Troy N. Trevino, Camillia S. Azimi, Amit K. Scheer, Haley E. Randolph, Thornton W. Thompson, Lily Zhang, Alexandre Iannello, Nikhita Mathur, Karen E. Jardine, Georgia A. Kirn, John C. Bell, Michael W. McBurney, David H. Raulet, Michele Ardolino. Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade. Journal of Clinical Investigation (2018) doi: 10.1172/JCI99317